EditorialEditorial

V. Palička

Clin Osteol 2013; 18(3): 67

Osteonecrosis of the jaw in patients receiving antiresorptive therapy of osteoporosisOriginal contributions

J. Rosa, G. Pavíková, V. Palička

Clin Osteol 2013; 18(3): 68-76

Osteonecrosis of the jaw (ONJ) is a known complication of high-dose antiresorptive therapy (AR) for bone malignancies, and is rarely (incidence rates of 1/10,000 and < 1/100,000 patient-years) seen also in patients receiving AR for osteoporosis. ONJ, defined as expo­ sure of thejaw bone lasting for more than 8 weeks, causes many complications. ONJ is frequently associated with an intervention in the oral cavity, which either accelerates its progression or is needed due to already existing ONJ. The dominant pathogenetic factor is likely to be decreased bone remodeling in the jaw bone tissue with physiologically high bone turnover, leading to changes...

Hypofosfatemická vitamín D rezistentní rachitida vázaná na X-chromozom: popis případu dvou sourozencůCase reports

P. Čamborová, V. Hůrková, L. Svitálková

Clin Osteol 2013; 18(3): 77-81

Adipose tissue and the skeleton - new insights into pathogenesis of osteoporosisOriginal contributions

D. Michalská

Clin Osteol 2013; 18(3): 82-86

Osteoporosis and obesity are chronic conditions with increasing prevalence rates. For a long time, they were considered separate en­ tities rarely found in a single individual. Recently, however, there has been growing evidence from clinical studies suggesting impor­ tant interactions between adipose tissue and the skeleton. Adipose tissue may influence bone remodeling by three mechanisms: (1) se­ cretion of endocrine cytokines and growth factors directly targeting the bone, (2) production of adipokines affecting the CNS and thus changing sympathetic impulses into the bone, and (3) paracrine effects on the adjacent bone cells (adipocytes in bone marrow)....

Giant-cell epulis: immunohistochemical analysis of MGMT, p53, OPN and MMP-1Original contributions

Y. Kuzenko, A. Romanyuk

Clin Osteol 2013; 18(3): 87-90

Object: The object of this study was to analyze the expression of MGMT, p53, OPN and MMP-1 in giant-cell epulis. Methods: 10 giant-cell epulis were evaluated for expression of MGMT, p53, OPN and MMP-1 by immunohistochemistry. Results: Strong giant-cell positivity for MGMT was observed in 96.9 ± 0.5 % (P < 0.05). Strong mesenchymal immunoreactivity for MMP-1 was figured in giant-cell, 75.9 ± 1.33 % and in the stroma 54.12 ± 1.36 % (P < 0.05). Immunoreactivity for OPN was fixed in the giant-cell of epulis 15.77 ± 1.8%., positivity for p53 was found in 5.67 ± 0.32 % of giant-cell contrast and in the stroma 0 %....

16th Congress Czech and Slovak OsteologistsAbstracts

Clin Osteol 2013; 18(3): 100-137